The Filing Desk

CorMedix

CRMD · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

CRMD · Last close · November 13, 2026
$4.66
Value CorMedix yourself

CorMedix's revenue rose 617.0% to $312 million in fiscal 2025. Its operating margin was 48.2%, up from −51.4% a year earlier. Free cash flow was $173 million. The diluted share count rose 36.4%.

CORMEDIX INC. Latest fiscal year ended December 31, 2025 10-K filed March 5, 2026 · 0001213900-26-023889 Updated
Revenue
$312M
617.0%
Operating margin
48.2%
99.6 pts
Net income
$163M
 
Free cash flow
$173M
 
Return on equity
66.6%
89.7 pts
Market cap
$366M
Nov 13 close
P/E
7.8x
On $0.60 EPS, 4 qtrs

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Share counts and per-share figures for earlier years are restated for a stock split (1-for-5), so every year is on today's share basis.

Charts show fiscal years, from the 10-K filings.

What CorMedix does

CorMedix sells drugs for life-threatening infections and conditions, mainly in hospitals and dialysis clinics. Its first product, DefenCath, is a lock solution placed in a catheter to reduce bloodstream infections in adults with kidney failure who get hemodialysis through a central venous catheter. The FDA approved it in November 2023, it launched in 2024, and it is the largest contributor to the company's net sales.

In August 2025 CorMedix bought Melinta Therapeutics, which added six marketed infection-fighting products sold to hospitals and clinics, among them REZZAYO, MINOCIN IV and VABOMERE, plus a heart drug, TOPROL-XL. The company focuses its promotion on DefenCath, REZZAYO, MINOCIN IV and VABOMERE.

It sells DefenCath to dialysis organizations under multi-year supply agreements. It is also seeking approval to use DefenCath in adults receiving nutrition through a vein, and to use REZZAYO to prevent fungal infections in patients with weakened immune systems. It says it also looks for deals that fit its sales team.

Its biggest risks, as it describes them

  • It has a history of operating losses and may not stay profitable, even though it earned a profit in 2025.
  • It depends on selling and winning insurance reimbursement for DefenCath and its other products in the U.S.
  • Its expansion into new uses for DefenCath and REZZAYO may not win FDA approval.
  • The Melinta purchase may not bring the benefits it expects.
  • It needs enough funding and manufacturing and sales arrangements to grow.
From CorMedix's annual report on Form 10-K, filed March 5, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow
Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments66597652148
Debt incl. finance leases————1
Net debt (negative means net cash)————−147
Net debt to EBITDA————−0.9x
Debt to equity————0.0x
Interest coverage−1,846.4x−1,155.0x−1,427.5x−621.0x54.0x
Current ratio12.4x9.4x7.0x3.4x2.1x
Quick ratio12.4x9.4x6.8x3.2x1.9x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project CorMedix's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What CorMedix says to expect

  • Full year 2026: revenue, EBITDA and operating costsThe Company maintains full-year 2026 consolidated revenue guidance of $325 to $345 million, narrows full-year adjusted EBITDA guidance to a range of $130 to $140 million from a range of $125 to $140 million, and reduces cash-based OpEx guidance to a range of $140 to $145 million from $145 to $155 million.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 12, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

No officer, director or 10% owner of CorMedix reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40——672.5%
Altman Z''−5.17−3.523.07
Accruals ratio−11.0%32.5%−2.5%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailPass
Cash from operations is positiveFailFailPass
Return on assets roseFailPassPass
Cash from operations exceeds net incomePassFailPass
Debt fell relative to assets———
Current ratio roseFailFailFail
Share count didn't riseFailFailFail
Gross margin rose——Fail
Revenue rose relative to assets——Pass
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put CorMedix side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
CorMedixFY25617.0%48.2%55.4%—−0.9x—
EvolusFY2511.6%−11.0%−15.4%−47.2%—2Compare
Ironwood PharmaceuticalsFY25−15.7%33.3%42.9%———Compare
Rigel PharmaceuticalsFY2564.2%42.6%—91.3%−0.8x7Compare
Xeris BiopharmaFY2543.7%8.5%—19.6%4.2x7Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue0000000—44312
Revenue growth6.7%47.0%30.5%−34.1%−15.6%−20.2%−65.7%——617.0%
Gross profit−000−0000—40276
Research and development1624191113131113419
Operating income−25−33−27−21−27−29−31−49−22150
Net income−25−33−27−16−22−28−30−46−18163
Diluted EPS (US$)−3.25−3.00−1.51−1.80−0.77−0.75−0.74−0.91−0.302.04
Diluted shares (millions)8111824293840515980
Cash flow
Cash from operations−22−29−24−15−22−21−24−38−51175
Capital expenditure0000010002
Free cash flow−22−29−24−15−22−23−25−39−51173
Dividends paid0000000000
Share buybacks0000000000
Acquisitions000000000308
Stock-based compensation12122546614
Balance sheet at fiscal year end
Cash and short-term investments201218284666597652148
Debt incl. finance leases—06——————1
Total assets2214193049696282119826
Total liabilities461465671234421
Shareholders' equity1875244463557085405
Margins and ratios
Gross margin−63.6%65.1%7.7%−31.8%14.4%22.0%94.3%—92.7%88.5%
Operating margin−11,048.8%−9,997.4%−6,250.4%−7,416.3%−11,378.4%−15,417.5%−46,819.9%—−51.4%48.2%
Net margin−10,996.5%−10,023.5%−6,242.4%−5,801.3%−9,207.7%−14,774.7%−45,409.9%—−41.2%52.3%
Free cash flow margin−9,961.5%−8,726.6%−5,525.7%−5,326.6%−9,229.7%−11,826.2%−37,573.5%—−116.7%55.4%
Rule of 40 (growth + FCF margin)−9,954.8%−8,679.7%−5,495.2%−5,360.8%−9,245.2%−11,846.4%−37,639.3%——672.5%
Return on capital——————————
Return on equity−95.1%−264.0%−442.5%−115.0%−64.9%−52.7%−50.4%−74.0%−23.2%66.6%
Return on assets−83.5%−186.7%−166.2%−68.0%−55.9%−47.7%−45.4%−64.3%−17.9%34.5%
Net debt to EBITDA—————————−0.9x
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: CorMedix's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with CorMedix.